The Hill Healthcare
- Industry
El-Sayed backs Jeffries' Medicare expansion as interim step
Sen.-elect Abdul El-Sayed (D-Mich.) said Tuesday he supports a Democratic proposal, endorsed by House Minority Leader Hakeem Jeffries, to lower Medicare's eligibility age, expand covered services and include children in the program. El-Sayed called the plan "a great start" in an interview with MS NOW's Jen Psaki, while saying it falls short of his preferred "Medicare For All" approach guaranteeing coverage to all Americans. The article notes Democrats campaigned on restoring Medicaid cuts from Trump's tax bill and funding lapsed ACA subsidies, and that some House progressives, including Rep. Ayanna Pressley, are pushing more sweeping reforms. President Trump is described as unlikely to support most Democratic policy priorities even with an expanded Democratic majority.
- Federal Policy
The Hill to Host Briefing on Alzheimer's Blood Test Screening Bill
The Hill, in partnership with HealthyWomen, is hosting a live policy briefing on the Alzheimer's Screening and Prevention Act (ASAP), bipartisan legislation that would allow Medicare to cover FDA-approved blood tests for Alzheimer's screening, which Medicare currently is not authorized to cover. The event features lawmakers, health experts, patients and advocates, and cites a HealthyWomen survey finding only 13 percent of women ages 45-64 are aware such blood tests exist, despite 90 percent expressing interest in taking one. The event also features This is ALZ, a HealthyWomen campaign highlighting experiences of people living with early-stage Alzheimer's. The briefing is scheduled to begin at 12:30 p.m. EST.
- Federal Policy
Sanders to Outline Senate Democrats' Healthcare Priorities
Sen. Bernie Sanders (I-Vt.) was set to outline Senate Democrats' healthcare priorities Wednesday morning, weeks after Democrats secured control of both chambers of Congress for next year. Sanders, who is poised to chair the Senate Health, Education, Labor and Pensions Committee, was also expected to renew his push for Medicare for All. The remarks follow Democrats' midterm focus on rising healthcare costs after enhanced Affordable Care Act subsidies expired last year, and come after the Trump administration withdrew its FDA commissioner nominee amid bipartisan opposition. The press conference was scheduled for 11 a.m. EST.
- Federal Policy
Sanders Plans Medicare for All Push as Likely HELP Chair
Sen. Bernie Sanders (I-Vt.) told the Associated Press he will push a four-year Medicare for All plan atop the Democratic agenda when he is expected to chair the Senate HELP Committee next year. The plan would lower the Medicare eligibility age to 55 in year one, add dental and vision coverage, guarantee coverage for children through age 18, then drop the eligibility age to 45 in year two and 35 in year three before covering all Americans in year four. Sanders views budget reconciliation as a path around a Senate filibuster, though the source notes President Trump would likely veto it. Speaker Hakeem Jeffries has separately endorsed lowering the Medicare eligibility age, while Sen.-elect Chris Pappas (D-N.H.) said his top priority is stopping an estimated $1 trillion in Medicaid cuts, and the House Budget Committee estimates Medicare for All would cost $32 trillion over 10 years.
- Federal Policy · TX
CDC Lets $29.2M Texas HIV Prevention Grant Expire
The CDC cut $29.2 million from HIV prevention programs in Texas by allowing a 2021 grant to expire on September 30, according to The Texas Tribune as reported by The Hill. The funding supported community organizations that cover HIV testing costs, connect people to care providers, and pay for antiviral medication. The cut follows broader reductions in federal HIV response funding, including cuts tied to USAID's elimination, reduced support for UNAIDS and PEPFAR, and the planned end of support for an HIV program in Namibia. Texas had one of the highest rates of new HIV infections in 2022, and a report found CDC-funded community tests diagnosed cases at three times the rate of local health department tests.
- Federal Policy
Rand Paul Seeks Top GOP Seat on Senate HELP Committee
Sen. Rand Paul (R-Ky.) said he is seeking the top Republican spot on the Senate Health, Education, Labor and Pensions Committee for the next Congress, giving up his current chairmanship of the Homeland Security Committee to do so. Paul is the most senior Republican on the HELP panel after former chair Bill Cassidy and other members, including Susan Collins and Roger Marshall, lost their elections. Paul said he would oppose a "rush toward socialism" and expects to spar with incoming chair Sen. Bernie Sanders (I-Vt.), who has prioritized expanding government-run health care.
- Legal
Democratic Lawmakers Demand Drugmakers Disclose MFN Deal Details
Congressional Democrats, including Reps. Frank Pallone Jr., Richard Neal, Bobby Scott and Sen. Ron Wyden, are demanding pharmaceutical companies disclose un-redacted details of their "most favored nation" drug pricing agreements with the Trump administration, according to a source familiar with the effort. If companies cannot provide the details, for example due to potential non-disclosure agreements with the White House, they were told to meet with lawmakers within two weeks to discuss how they will fulfill the request. The same four lawmakers sent a similar letter in March that the administration did not answer. Lawmakers want to know what drug companies are receiving in exchange for agreeing to lower prices for Medicaid, and to verify administration claims about savings to the public.
- Federal Policy
Sanders calls for Democrats to pass 'Medicare for All'
- State Policy · VA
Virginia Voters Enshrine Abortion, Reproductive Rights in Constitution
Virginia voters approved a ballot measure Tuesday adding reproductive freedom protections to the state constitution, according to Decision Desk HQ projections. The amendment constitutionalizes existing protections for abortion, birth control, and in-vitro fertilization, and also covers fertility care, pregnancy-related care, and miscarriage care. The measure locks current access into the constitution, making it harder for future legislatures to restrict these services. The change affects reproductive health policy broadly in Virginia, though the article does not describe specific Medicaid coverage or reimbursement provisions.
- Industry
KFF Reports ACA Marketplace Premiums to Rise 13% in 2027
KFF reports that average Healthcare.gov marketplace premiums will rise 13 percent in 2027, following a 26 percent increase from 2025 to 2026. The back-to-back double-digit hikes affect individual-market enrollees who buy coverage through the ACA exchanges rather than through employer or Medicaid coverage. The increases take effect with 2027 plan year pricing. KFF's findings highlight continued affordability pressure in the ACA marketplace, which analysts attribute in part to rising medical costs and uncertainty over enhanced subsidy extensions.
- Federal Policy
Senate Democrats Question Insurers on ACA Fraud Terminations
Senate Democrats Ron Wyden and Bernie Sanders sent letters Monday to CEOs of the 10 largest Affordable Care Act insurers, questioning their cooperation with the Trump administration's effort to terminate coverage for thousands of ObamaCare enrollees over alleged fraud. The lawmakers are seeking information on how insurers identified affected enrollees and what due process protections, if any, were provided before coverage was cut off. No specific compliance deadline was cited in the letters. The inquiry signals heightened congressional scrutiny of marketplace program integrity actions and their impact on enrollee access to coverage.
- Federal Policy
Trump Announces $250 Million Nursing Home Nurse Staffing Initiative
President Trump announced Monday evening via Truth Social a federal and state initiative worth more than $250 million aimed at recruiting and retaining nurses for nursing homes. Details on the specific funding mechanism, implementation timeline, and which agencies will administer the program were not included in the announcement. Nursing homes, many of which serve large populations of Medicaid-eligible long-term care residents, have faced persistent staffing shortages that affect care quality and regulatory compliance. Further guidance is expected to clarify how states and facilities can access the funds.
- Federal Policy
Medicare Open Enrollment Opens With Higher Costs, GLP-1 Coverage Shifts
Medicare's annual open enrollment period has begun, giving beneficiaries until early December to review 2027 plan options amid several cost changes. Seniors face higher deductibles next year, along with new considerations around coverage and pricing for GLP-1 weight-loss and diabetes drugs. The changes affect Medicare Advantage and Part D enrollees who must compare plans to avoid unexpected out-of-pocket costs. While this story centers on traditional Medicare rather than Medicaid, dual-eligible beneficiaries and state Medicaid programs that coordinate benefits with Medicare should monitor how these cost shifts affect dual-eligible populations.
- Industry
Democrats Target Republicans Over Medicaid Cuts in Midterm Ads
Democrats in competitive congressional districts are attacking Republican incumbents over their votes for the One Big Beautiful Bill law, which cuts Medicaid funding by nearly $1 trillion to help finance tax cuts. The attacks are showing up in campaign advertisements and debates ahead of the midterm elections, with Republicans reportedly struggling to craft a consistent defense of the law's Medicaid provisions. No new policy action is described; the article covers campaign messaging and political positioning around the existing law. The dynamic signals Medicaid funding cuts remain a potent, unresolved political liability heading into the midterms.
- Industry
Compounded GLP-1 Drugs Recalled Nationwide Over Safety Concerns
A nationwide recall has been issued for certain compounded GLP-1 medications, which are not FDA-approved and are not the same as brand-name versions like Ozempic or Wegovy. These compounded products, often made by compounding pharmacies to meet demand or offer lower-cost alternatives, are being pulled due to safety concerns. Patients and providers who have obtained these non-FDA-approved versions are affected and should check with suppliers for specifics on the affected lots. Details on the scope, triggering safety issue, and timeline were not specified in the source material.
- Industry
UnitedHealthcare, Humana Cut Medicare Advantage Plans Affecting 1 Million
UnitedHealthcare and Humana are discontinuing Medicare Advantage plans that will affect roughly 1 million enrollees, with most terminated plans being Preferred Provider Organizations that offer broader provider network flexibility compared to HMOs. Affected members will need to select new Medicare Advantage plans or return to traditional Medicare during the upcoming enrollment period. The cancellations reflect insurers' efforts to control costs amid rising medical expenses and reduced federal reimbursement rates in the Medicare Advantage program.
- State Policy · PA
Pennsylvania Alerts Doctors to Rise in Congenital Measles Cases
Pennsylvania's health department issued an alert to physicians Monday warning of an increase in measles cases among pregnant women and growing concern about congenital measles, a condition rarely seen in the U.S. in which a newborn contracts measles from the mother. The department said this marks the first identification of congenital measles in the state in recent memory. The alert urges clinicians to watch for symptoms in newborns and pregnant patients and to report suspected cases. No specific policy or coverage changes were announced alongside the clinical warning.
- Federal Policy
HHS Launches National Kidney Care Plan to Cut Costs
The Trump administration launched the Kidney Care National Plan on Tuesday, an HHS initiative aimed at addressing structural deficiencies in kidney disease care that the department says drive up costs and lower quality of care. The plan targets the broader health care system's handling of chronic kidney disease and end-stage renal disease, populations that include a significant share of Medicaid and Medicare beneficiaries. Details on specific mechanisms, funding, or implementation timelines were not fully outlined in the initial announcement. HHS frames the effort as a response to longstanding gaps in prevention, early detection, and treatment coordination for kidney disease patients.
- Federal Policy
Trump Signs Order Creating NIH Women's Health Division
President Trump signed an executive order establishing a new women's health initiative led by first lady Melania Trump, creating a Women's Health Division at NIH and a White House Women's Health Task Force. The initiative is organized around five pillars identified by the first lady, though specific program details and funding mechanisms were not fully outlined in initial reporting. The order was first reported by USA Today. The task force and NIH division will shape federal research and policy priorities on women's health going forward.
- Industry
Health Insurance Premium Spikes Emerge as Midterm Election Issue
Americans are facing sharply higher health insurance costs next month, whether they hold ACA marketplace plans or employer-sponsored coverage, with some premiums reaching decades-high levels. Others will see costs shift to out-of-pocket expenses like copays and deductibles rather than premiums themselves. The piece frames rising health costs as an underappreciated political issue heading into the midterm elections, as consumers across coverage types feel the squeeze simultaneously. The report does not detail a specific policy action but surveys broad cost pressures affecting insured Americans nationally.
- Federal Policy
FDA Sends Peptide Compounding Access Policy to White House
The FDA this week submitted an "interim access policy" for peptides to the White House for regulatory review, according to a government filing. The policy would reportedly let compounding pharmacies temporarily produce and sell peptide products previously restricted by FDA rules. The filing does not specify a timeline for release or implementation. Details on scope, affected products, and effective dates remain unclear pending White House review.
- Industry
KFF: Individual Market Enrollment Fell 18 Percent in a Year
KFF reports that individual health insurance market enrollment, including ACA marketplace plans, dropped from 25.2 million in 2025 to 20.5 million in June 2026, an 18 percent decline and the largest year-over-year drop on record. The analysis attributes the falloff to changes affecting subsidized marketplace coverage. Many people losing individual market coverage may become uninsured or shift to other coverage sources, including Medicaid where eligible. The decline signals broader coverage disruption that could increase uncompensated care and churn across state insurance markets.
- Legal
CVS to Pay $315M Settling Opioid Prescription Claims
The Justice Department announced that CVS Health agreed to pay $315 million to settle allegations that the company illegally filled prescriptions for opioids and other controlled substances. The settlement resolves a lawsuit first filed in 2019 by former CVS employee Hillary Estright under a whistleblower provision. The announcement does not specify the breakdown of federal versus state recoveries or how much, if any, relates specifically to Medicaid-reimbursed prescriptions. CVS operates pharmacy benefit and retail pharmacy services that interact with Medicaid beneficiaries across many states, making controlled-substance dispensing practices relevant to program integrity oversight.
- Federal Policy
DEA Moves to Restrict Synthetic Kratom Extract 7-OH
Federal authorities and lawmakers are increasing scrutiny of concentrated kratom extracts, including a compound known as 7-OH, sold over the counter in most states as the so-called "gas station opioid." The DEA earlier this year announced plans to temporarily ban products containing elevated concentrations of the substance, citing public health risks. The products are currently unregulated at the federal level in most jurisdictions, raising concerns about potency, labeling, and abuse potential. Increased federal attention signals possible scheduling action or new restrictions affecting product availability nationwide.
- Federal Policy
Pallone Introduces Bill to Overhaul Surprise Billing Dispute Process
Rep. Frank Pallone Jr. (D-N.J.), ranking member of the House Energy and Commerce Committee, has introduced legislation to revise the independent dispute resolution (IDR) process under the No Surprises Act. The bill targets what Pallone and other critics describe as a flawed system for resolving payment disagreements between insurers and providers. Details on specific reforms, timing, and committee action were not provided in the source material.
- Legal
GAO Finds HHS Illegally Withheld AHRQ Research Funds
The Government Accountability Office found that HHS violated the Impoundment Control Act by withholding tens of millions of dollars in congressionally appropriated research grant funding for the Agency for Healthcare Research and Quality (AHRQ). The GAO report, released Wednesday, concludes the Trump administration unlawfully held back funds Congress had designated for AHRQ research grants. The finding adds to a broader pattern of impoundment disputes between the administration and Congress over appropriated health-related funding. The report does not detail a court remedy but establishes a legal basis for further congressional or judicial action to compel release of the funds.
- Federal Policy
FDA Delays Mifepristone Safety Review Until March
The FDA disclosed in a Wednesday court filing that it will not complete its safety review of the abortion drug mifepristone until March, and will not impose new restrictions on the drug before then. The disclosure comes amid pressure from anti-abortion activists who have grown impatient with the pace of the agency's review. The delay means current prescribing and dispensing rules for mifepristone remain unchanged in the interim. The review's eventual outcome could affect access rules that touch Medicaid-covered reproductive health services in states where the program covers medication abortion.
- Industry
KFF Poll Finds Medicare for All Support Rises to 66 Percent
KFF published new polling Tuesday showing 66 percent of U.S. adults now favor a national, single-payer health plan, the highest level of support since 2016. The survey found 32 percent of respondents "strongly" favor the idea, with support spanning broad demographic groups though varying by party affiliation. The poll does not reflect a specific policy proposal or legislative action, but tracks shifting public opinion on health coverage structure. No implementation timeline or legislative vehicle is attached to the findings.
- Legal
Appeals Court Weighs DOJ Bid to Reinstate Kennedy's Vaccine Panel Picks
The Trump administration argued before the 1st U.S. Circuit Court of Appeals that a district court judge lacked authority to block Health Secretary Robert F. Kennedy Jr.'s appointees from serving on a key federal vaccine advisory panel. Justice Department attorney Matthew Zorn contended the lower court erred in its ruling. The appeals panel has not yet issued a decision on whether the injunction blocking the appointments will stand. The case centers on control over vaccine policy recommendations that influence immunization schedules nationally.
- Federal Policy
Trump Pledges Cash Payments to Medicare, ACA Enrollees
Facing voter frustration over healthcare costs ahead of the midterm elections, President Trump has pledged direct cash payments to Americans enrolled in federal health programs. The pledges include $90 payments to tens of millions of Medicare beneficiaries and $500 payments tied to ACA marketplace coverage. Details on funding mechanisms, eligibility, and implementation timelines have not been finalized. The announcements come as Republicans seek to counter political pressure over rising health costs heading into the election.
- State Policy · NY
Hochul Declares Disaster Emergency Over New York Measles Outbreak
New York Gov. Kathy Hochul declared a statewide disaster emergency Monday in response to a measles outbreak that has sickened 108 people as of Oct. 3, with most cases occurring outside New York City. The declaration marks the state's first disaster emergency of the year and is intended to mobilize additional public health resources to contain the outbreak. Seven cases have occurred in New York City itself, according to state officials. The move signals an escalating public health response that will likely involve vaccination campaigns and coordination with local health departments and providers.
- State Policy · PA
Pennsylvania Measles Outbreak Tops 1,000 Cases, Five Deaths
Pennsylvania's Department of Health dashboard update Monday shows 1,004 measles cases recorded statewide this year, including 198 hospitalizations and five deaths, making it the largest state outbreak in the current national surge by a wide margin. About a third of cases fall into an unspecified category noted in the update. The scale of hospitalizations and pediatric exposure raises implications for the state's Medicaid program, which covers a large share of affected children and families through EPSDT and emergency care benefits. State and local health officials continue to track case growth as the outbreak outpaces other states.
- Industry
KFF Poll Finds Voters Trust Democrats More on Health Costs
A new KFF poll finds health care affordability remains a top voter concern, with six in 10 respondents worried about being able to afford health care and insurance costs. Voters trust Democrats over Republicans on health care costs by nearly a two-to-one margin. The poll reflects broader public sentiment on health policy rather than a specific Medicaid proposal or program change. Findings could shape messaging and political pressure around health care affordability debates heading into upcoming elections.
- Federal Policy
HHS Finalizes Updated Hospital Price Transparency Rule
HHS, the Employee Benefits Security Administration, and the IRS finalized amendments to the hospital price transparency rules first established during President Trump's first term. The changes aim to make hospital pricing data more accessible and understandable for patients and other users of the data. The rule applies broadly to hospitals and group health plans rather than specifically to Medicaid programs. Further detail on effective dates and specific data requirements was not included in the source material.
- Federal Policy
Medicare Improvement Fund Sends $90 One-Time Payments to Seniors
The Trump administration is distributing one-time $90 payments to qualifying Medicare beneficiaries, funded through the Medicare Improvement Fund, arriving as direct deposits or paper checks. The source does not detail specific eligibility criteria beyond framing the payments as targeted at seniors enrolled in Medicare. No information is provided on an application process, exact distribution timeline, or whether dual-eligible Medicaid beneficiaries are included. Details on funding mechanism and scope remain limited in the reporting.
- Federal Policy
Senate Democrats Demand Answers on Preventive Task Force Overhaul
Sen. Angus King (I-Maine) and 16 other Senate Democrats sent a letter to HHS Secretary Robert F. Kennedy Jr. demanding answers about his recent overhaul of the U.S. Preventive Services Task Force, the expert panel that determines which preventive services insurers must cover without cost-sharing. The senators are pressing HHS on the rationale and process behind the changes to the panel's composition. No deadline for HHS response is specified in the available reporting. The task force's recommendations shape coverage mandates across commercial insurance and have downstream influence on Medicaid benefit design and quality benchmarks.
- Federal Policy
RFK Jr., Oz to Unveil Health Price Transparency Initiative
HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz are set to announce new health care price transparency efforts Monday, joined by Labor Secretary Keith Sonderling, Deputy Treasury Secretary Francis Brooke, and the FTC Chair. The announcement spans multiple federal agencies, suggesting a coordinated cross-government push rather than a single CMS rule. Details on the specific policy actions, scope, and effective dates were not available ahead of the event. The multi-agency involvement signals the initiative may touch pricing disclosure requirements across commercial, employer-sponsored, and government health coverage.
- Federal Policy
Grassley Urges Trump Administration to Finalize Kratom Rule
Sen. Chuck Grassley (R-Iowa) publicly pressed the Trump administration to finalize a proposed rule restricting sale of 7-hydroxymitragynine (7OH), a concentrated kratom compound, calling the substance deadly and demanding it be pulled from gas stations, vape shops, and other retail outlets. The statement does not specify a new regulatory action by the administration, but amplifies pressure on FDA/DEA to move from proposed to final rule status. No effective date is given, as the underlying rule remains unfinalized. The push concerns a substance regulated outside typical Medicaid pharmacy channels, though it intersects with broader opioid-use and behavioral health policy concerns.
- Federal Policy
Senate Democrats Question HHS Over Delayed Pediatric COVID Vaccine Access
Senate Minority Leader Chuck Schumer and other top Senate Democrats sent a letter to CDC Director Erica Schwartz and HHS Secretary Robert F. Kennedy Jr. questioning an apparent delay in making COVID-19 vaccines available to low-income children through a federal program. The lawmakers are seeking answers about why access through this program has stalled and what HHS plans to do to restore timely vaccine availability. The letter does not specify a response deadline in available reporting. Low-income children who rely on federally funded vaccine access programs, often coordinated with state Medicaid and CHIP populations, are the primary group affected by any delay.
- Federal Policy
Trump Administration Withholds Health Funds Before Fiscal Year Deadline
The Trump administration has declined to spend billions of dollars in congressionally appropriated health program funding, risking its expiration at the fiscal year-end on Wednesday. Democratic lawmakers and some Republicans argue the withholding violates federal law governing appropriated funds. The impasse tests whether Congress will act to compel spending of the funds before they lapse. The story does not specify which health programs or dollar amounts are affected.
- Industry
RFK Jr., Vance Headline MAHA Summit on Health Policy Agenda
HHS Secretary Robert F. Kennedy Jr. and Vice President JD Vance are leading a daylong "Make America Healthy Again" summit in Washington on Tuesday, gathering Trump administration officials, health care and tech executives, and MAHA allies. Sessions cover health care affordability, food policy, and artificial intelligence, among other topics. The event is a policy and messaging forum rather than a rulemaking action, but it signals priorities that could shape future administration health initiatives. No specific Medicaid policy announcements are described in the available details.
- Industry · ME
Democratic Super PAC Airs Ad Tying Collins to Medicaid Cuts
The Senate Majority PAC, a Democratic super PAC, launched an ad campaign attacking Sen. Susan Collins (R-Maine) over the closure of about a dozen birthing centers in Maine, linking the closures to Medicaid cuts in the One Big Beautiful Bill Act. The ad argues Collins enabled the cuts despite voting against the final legislation. The campaign is part of ongoing 2026 midterm messaging tying federal Medicaid reductions to state-level provider closures, particularly in maternal health services. No new policy or funding action is described; this is a political advertising campaign referencing prior Medicaid legislation.
- Industry
Novo Nordisk's Trial Drug Outperforms Zepbound in Weight Loss
Novo Nordisk reports that its experimental next-generation obesity drug, positioned as a successor to Wegovy, produced greater weight loss than Eli Lilly's Zepbound in a head-to-head clinical trial. The result intensifies competition in the GLP-1 weight-loss drug market between the two dominant manufacturers. No regulatory approval or launch timeline was announced, and pricing or Medicaid coverage decisions are not yet at issue. For Medicaid stakeholders, the news signals that pipeline competition in this drug class will continue to grow, with implications for future coverage and cost pressure once new products reach market.
- Federal Policy
Senate Democrats Question Kennedy Ethics Compliance on Vaccine Lawsuit Divestment
Senate Democrats are questioning whether HHS Secretary Robert F. Kennedy Jr. potentially violated his ethics agreement by allegedly concealing an arrangement to collect money from a settlement with a vaccine manufacturer. Kennedy pledged to divest from the lawsuit during his confirmation process last year. The senators' inquiry raises concerns about potential conflicts of interest at the federal agency overseeing Medicaid and other health programs. The matter is significant for Medicaid stakeholders because Kennedy's leadership of HHS includes oversight of CMS, which administers the Medicaid program and sets immunization policy affecting coverage requirements for state programs and managed care plans.
- Federal Policy
Trump Administration Terminates ACA Coverage for 750K Enrollees Citing Fraud
The Trump administration announced Tuesday it will terminate Affordable Care Act marketplace coverage for approximately 750,000 enrollees identified as fraudulent, according to Vice President Vance. The administration estimates the cancellations will save $2.2 billion in federal subsidies. CMS Administrator Dr. Mehmet Oz stated the terminated enrollments represent non-existent individuals. The announcement did not specify an effective date for the terminations or detail the criteria used to identify fraudulent enrollment.
- Federal Policy
All States Apply for CMS Medicaid Drug Pricing Program
All 50 states, Washington, D.C., and Puerto Rico have applied to participate in a CMS arrangement designed to reduce Medicaid drug costs, with 40 states and Puerto Rico already signing agreements. President Trump announced the milestone Friday, characterizing the program as delivering significant savings to state Medicaid programs. The timing and specific mechanics of the drug pricing arrangement were not detailed in the announcement. The development signals broad state interest in federal cost-containment tools for Medicaid pharmacy spending.
- Federal Policy
White House Announces 50-State Medicaid Drug Pricing Initiative
President Trump will announce that all 50 states will implement "most favored nation" pricing for certain Medicaid-covered drugs, according to an administration official. The announcement, scheduled for Friday with several governors present, would tie Medicaid drug prices to lower international reference prices. Implementation details including which drugs are covered, effective dates, and how this aligns with existing Medicaid best price and rebate requirements remain unclear. The initiative reflects ongoing White House focus on drug affordability as a voter priority.
- Federal Policy
HHS Secretary Kennedy Tells Anti-Vaccine Group Administration Supports Its Cause
HHS Secretary Robert F. Kennedy Jr. told Children's Health Defense, an anti-vaccine organization he previously led, that the Trump administration is a "strong and steadfast friend" to the group's cause. The remarks were delivered Thursday at a one-day conference. The statement signals potential alignment between federal health policy leadership and vaccine skepticism advocacy. This raises questions about future federal vaccine policy direction, including recommendations affecting Medicaid pediatric EPSDT requirements and childhood immunization standards.
- Legal · TX
Texas Family Sues Attorney General Paxton Over Denied Abortion Leading to Maternal Death
The family of Tierra Walker, a 37-year-old Texas woman who died from preeclampsia in 2024, filed a lawsuit Wednesday against Texas Attorney General Ken Paxton and doctors who denied her an abortion. Walker experienced seizures, blood clots, and hypertensive crisis at four months pregnant and requested abortion care multiple times before her death. The lawsuit challenges enforcement of Texas abortion restrictions that allegedly prevented medically necessary care. This case follows several wrongful death and civil rights lawsuits filed nationwide challenging state abortion laws and their impact on maternal health outcomes.
- Federal Policy
HHS Secretary Kennedy to Keynote Anti-Vaccine Group Conference
HHS Secretary Robert F. Kennedy Jr. is scheduled to deliver a keynote address at a Children's Health Defense conference this week. CHD is an anti-vaccine advocacy organization Kennedy co-founded and led before his appointment as HHS Secretary. Kennedy has attempted to distance himself from the organization over the past year. The appearance raises questions about potential conflicts between his official role overseeing federal health policy, including Medicaid, and his ongoing relationship with an organization that opposes vaccine mandates and promotes vaccine skepticism.
- Federal Policy
22 States Sue DHS Over Public Charge Rule Affecting Immigrant Access to Benefits
A coalition of 22 Democratic-led states and Washington, D.C., filed suit against the Department of Homeland Security to block implementation of the public charge rule. The rule restricts green card eligibility for immigrants who use or are likely to use public benefits. The litigation challenges whether DHS exceeded its authority and whether the rule violates statutory requirements. For state Medicaid agencies, the rule affects enrollment and coverage decisions for lawfully present immigrants, particularly in states that extend Medicaid eligibility beyond the federally required minimum.
- Industry
Half of Hospitals Comply with Federal Price Transparency Rules, Report Finds
Patient Rights Advocate reported that 49.4% of U.S. hospitals are in full compliance with federal price transparency requirements as of September 2026, representing the highest compliance rate since the rule took effect. The report marks the eighth assessment by the nonprofit monitoring hospital adherence to CMS price disclosure requirements. While compliance has improved incrementally, over half of hospitals remain noncompliant with federal mandates to publish machine-readable files of negotiated rates with commercial payers and cash prices.
- Managed Care
GLP-1 Prescriptions for Children Rose 30,000 Percent Since 2019
Prescriptions of GLP-1 medications for children increased more than 30,000 percent between 2019 and present, according to new data. Children with obesity-related conditions such as high cholesterol or sleep apnea were substantially more likely to receive GLP-1 prescriptions than those without these comorbidities. The dramatic rise in pediatric GLP-1 use reflects growing clinical acceptance of these medications for weight management in children with obesity-related health complications. This trend has significant implications for Medicaid managed care pharmacy budgets and prior authorization protocols, as GLP-1s are high-cost specialty medications and children represent a growing share of Medicaid enrollment.
- Legal
Fifth Circuit to Hear Mifepristone Access Case Amid Medicaid Coverage Implications
A three-judge panel on the Fifth Circuit Court of Appeals will hear oral arguments in a case challenging nationwide distribution of mifepristone, the medication abortion drug. The case could result in restrictions on mifepristone access that would affect Medicaid beneficiaries and state Medicaid pharmacy programs. Oral arguments are scheduled for next week, with a decision timeline uncertain. The outcome could require state Medicaid agencies and managed care plans to adjust pharmacy benefits, provider networks, and utilization management protocols for medication abortion services covered under Medicaid.
- Industry
Bipartisan House Bill Proposes $35 Monthly Insulin Cap for Private Insurance
House lawmakers introduced bipartisan legislation Thursday to cap monthly insulin costs at $35 for people with private health insurance. The bill includes support from two battleground Republicans, marking a shift from previous GOP resistance to government price-setting. If enacted, the cap would affect privately insured patients; Medicaid beneficiaries already benefit from rebate protections and state-specific cost-sharing limits that often result in lower out-of-pocket costs. The legislation has been discussed for years but has not previously advanced due to concerns about government price controls.
- Federal Policy
Democrats Debate Healthcare Reform Priorities Ahead of 2026 Midterms
Democratic lawmakers and policy groups are proposing various healthcare reform options as the party campaigns to retake Congress in the 2026 midterm elections. The debate follows the 2025 expiration of enhanced ACA premium tax credits, with no current legislative momentum to extend them. Proposals under discussion range from incremental ACA fixes to more expansive reforms. The outcome will depend on election results and intraparty consensus on how aggressively to pursue healthcare changes, which could affect Medicaid expansion efforts, marketplace subsidies that interact with Medicaid eligibility, and broader coverage policy.
- Federal Policy
Acting Attorney General Signals Federal Action to Restrict Abortion Access in All States
Acting Attorney General Todd Blanche told faith leaders on a private call hosted by the White House Faith Office that he plans to roll back abortion access nationwide, including in states with protective abortion laws. Blanche indicated the administration intends to reverse Biden-era protections for abortion access. The timeline and specific legal mechanisms for federal intervention were not detailed in available reporting. The development is significant for state Medicaid agencies and managed care organizations that cover abortion services under state law, potentially creating conflicts between federal directives and state coverage obligations.
- Federal Policy
Trump Executive Order Reduces Recommended Childhood Vaccine Schedule to 11 Core Immunizations
President Trump signed an executive order Monday advancing 'Make America Healthy Again' priorities by recommending 11 core childhood vaccinations instead of the current CDC schedule and directing agencies to split combined vaccines. The order takes effect immediately but applies only to federal recommendations, not state Medicaid EPSDT requirements, which mandate coverage of ACIP-recommended immunizations under federal law. The directive creates potential conflict between federal guidance and mandatory Medicaid Early and Periodic Screening, Diagnostic and Treatment benefits. State Medicaid agencies and managed care plans must continue covering all ACIP-recommended vaccines to maintain federal compliance and avoid audit findings.
- Federal Policy
Trump Administration Announces Medicaid Drug Pricing Agreements with Nine Companies
The Trump administration announced new Medicaid drug pricing agreements with nine midsize biotechnology and pharmaceutical companies. Under the agreements, companies will charge state Medicaid programs prices equal to the lowest available globally. President Trump stated the deals will apply to every drug from participating firms. The announcement was made Monday in the Oval Office with company executives present.
- Legal
23 States Sue Trump Administration Over Family Planning Grant Requirements
A coalition of 23 states filed suit in Maryland federal court Thursday challenging new conditions on family planning grants that would allegedly require states and providers to align with administration political priorities or lose federal funding. The lawsuit contests restrictions that could affect Title X family planning program funding, which supports reproductive health services including contraception and preventive care for Medicaid beneficiaries. The litigation seeks to block implementation of the new grant requirements. The outcome will determine whether states retain existing federal family planning funding or must choose between compliance with new federal conditions and maintaining current service delivery models.
- Federal Policy
Senate Democrats Question HHS Secretary Kennedy on HPV Vaccine Lawsuit Divestment
Senate Democrats are scrutinizing whether HHS Secretary Robert F. Kennedy Jr. fully divested his financial interests in ongoing litigation against Merck's HPV vaccine Gardasil before his confirmation. Kennedy was involved in a lawsuit led by Wisner Baum challenging the vaccine prior to his appointment. The inquiry raises questions about potential conflicts of interest at the top of the agency that oversees Medicaid coverage policy, vaccine programs, and federal health initiatives. The matter could affect federal vaccine policy direction and Medicaid immunization coverage decisions.
- Industry
GLP-1 Medications Show Potential to Treat Addiction, Emerging Research Suggests
Emerging research indicates that GLP-1 medications, widely used for obesity and diabetes treatment, may help treat addiction disorders. The studies add to a growing list of unanticipated effects associated with this drug class. The findings are preliminary and do not yet reflect approved indications or clinical practice guidelines. If further research confirms these effects and leads to FDA approval for addiction treatment, Medicaid programs could face coverage decisions for a new high-cost indication with significant budget implications.
- Federal Policy
HHS Secretary Kennedy Implements Executive Order Reducing Childhood Vaccines
President Trump signed an executive order to reduce childhood vaccines, with HHS Secretary Robert F. Kennedy Jr. present and implying a link between vaccines and autism. The order affects federally-funded vaccine programs, including those administered through Medicaid and CHIP. Implementation details and timing are not yet specified. The change carries implications for state Medicaid agencies and managed care plans responsible for EPSDT requirements and vaccine coverage mandates.
- Federal Policy
CMS Administrator Oz States MMR Vaccine Not Lethal, Contradicts Trump
Dr. Mehmet Oz, CMS Administrator, stated publicly that the MMR vaccine is not lethal, contradicting President Trump's characterization. The statement was made during a CBS News interview on August 23, 2026. This matters for Medicaid because CMS oversees Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits, which require comprehensive immunizations for eligible children, including MMR. Any policy shift on vaccine guidance from CMS leadership could affect state Medicaid agency compliance with federal EPSDT requirements and managed care organization vaccine administration protocols.
- Federal Policy
Estrogen Patch Shortage Continues as Manufacturers Cite Federal Policy-Driven Demand Spike
Pharmaceutical manufacturers report ongoing supply shortages of estrogen patches in the U.S., attributing the shortage to increased demand following federal policy changes implemented earlier in 2026. The manufacturers flagged supply issues earlier this year but federal regulators have not yet officially recognized a shortage. The continued supply constraints affect Medicaid beneficiaries' access to hormone replacement therapy, potentially forcing plans and providers to manage formulary alternatives and prior authorization processes for affected members seeking this form of estrogen therapy.
- Legal
Federal Court Blocks Trump Administration Changes to Teen Pregnancy Prevention Grants
A federal district court in Washington, D.C., issued a temporary injunction halting the Trump administration's changes to the Teen Pregnancy Prevention (TPP) program that cut tens of millions in federal grants. The order pauses the administration's changes pending further litigation. The ruling affects organizations that lost federal funding abruptly under the policy shift. The injunction takes effect immediately.
- Industry
Trump Nominates White House Health Adviser Heidi Overton as FDA Commissioner
President Trump announced Wednesday he will nominate Dr. Heidi Overton, currently a White House domestic policy adviser on health issues, to serve as FDA Commissioner. The nomination comes amid significant staff turnover at the agency. If confirmed by the Senate, Overton would lead the FDA's oversight of prescription drugs, including Medicaid drug coverage policy and pharmaceutical manufacturer rebates. The nomination's impact on Medicaid will depend on Senate confirmation timing and Overton's policy priorities once in office.
- Legal
Democratic Senators Accuse HHS of Violating Court Order on Medicaid Data Sharing with ICE
Four Democratic senators accused the Trump administration of violating a court order by continuing to share Medicaid enrollment data with DHS and ICE for deportation proceedings. Sens. Wyden, Booker, Merkley, and Van Hollen demanded HHS immediately halt the data sharing practice. The complaint alleges ongoing transfers of beneficiary information despite judicial restrictions. The disclosure raises compliance and enrollment concerns for state Medicaid agencies managing beneficiary data and MCOs responsible for protecting member information under privacy regulations.
- Federal Policy
March of Dimes: 5.8 Million Women Live in Maternity Care Deserts
A March of Dimes report finds that 5.8 million women live in counties without full access to maternity care, with one-third of U.S. counties classified as maternity care deserts — areas lacking hospitals or birth centers offering obstetric services. The report highlights geographic disparities in prenatal and delivery care access nationwide. These gaps affect Medicaid-covered pregnancies, as Medicaid finances approximately 42% of births nationally and faces network adequacy and provider participation challenges in underserved areas.
- Industry
Research Suggests GLP-1 Drugs May Reduce Birth Control Effectiveness and Boost Fertility
Emerging research indicates that GLP-1 receptor agonist medications may interfere with oral contraceptive effectiveness and potentially increase fertility in users. The mechanism appears related to GLP-1s' effects on gastric emptying and hormone metabolism, which could reduce contraceptive absorption and alter reproductive hormone levels. The timing and clinical significance remain under investigation, but the findings have immediate implications for prescribing guidance and patient counseling. For Medicaid programs covering GLP-1s for diabetes and obesity, this raises questions about contraceptive coverage coordination, prior authorization criteria, and member education protocols.
- Federal Policy
HHS Secretary Kennedy Endorses Measles Vaccine Amid Outbreak Discussions
Health and Human Services Secretary Robert F. Kennedy Jr. endorsed the measles vaccine during a CNN interview on August 3, 2026, while making additional claims about other vaccines and RSV during ongoing measles outbreaks. The statement represents the Secretary's public position on measles immunization policy as the nation's top health official. The endorsement comes as federal and state health agencies manage measles outbreak response and vaccination campaigns. HHS guidance on childhood vaccinations influences state Medicaid EPSDT requirements, managed care quality metrics, and VFC program administration.
- Legal
HRC Sues Trump Administration Over Gender-Affirming Care Coverage Ban in Federal Employee Health Plans
The Human Rights Campaign filed a class-action lawsuit Monday challenging the Trump administration's ban on gender transition treatment coverage in federal employee health plans. The suit alleges the coverage ban violates federal sex discrimination protections in employment. The lawsuit does not directly target Medicaid or CHIP programs, though similar coverage restrictions could inform future Medicaid policy debates. The case centers on Federal Employees Health Benefits Program coverage, not state Medicaid programs.
- Federal Policy
HHS Secretary Kennedy Says Trump Directed Investigation of Autism-Vaccine Link
HHS Secretary Robert F. Kennedy Jr. stated in a CNN interview that President Trump has directed him to investigate perceived links between autism and vaccines. Kennedy confirmed the Wall Street Journal's reporting on the matter. The statement signals potential federal review of vaccine policy and safety monitoring under the current administration. No timeline or specific investigative framework has been announced.
- Federal Policy
Bipartisan Bill Directs CMS to Add Stuttering Screening to EPSDT
Sens. Jim Banks (R-Ind.) and Andy Kim (D-N.J.) introduced the Kidd's Stuttering Act on Wednesday, directing CMS to add stuttering and fluency screening to Early and Periodic Screening, Diagnostic and Treatment (EPSDT) services. The legislation would require Medicaid to cover screening and treatment for stuttering in children enrolled in the program. If enacted, state Medicaid agencies and managed care organizations would need to ensure network adequacy for speech-language pathology services and update coverage policies to include fluency disorder screening as part of well-child visits.
- Federal Policy
FDA Raises Safety Concerns About Compounded GLP-1 Drugs as Alternative to Ozempic
The FDA and physicians are expressing concern about compounded versions of GLP-1 drugs like Ozempic, which patients are increasingly using as cheaper, more accessible alternatives. These compounded formulations, while easier to obtain, carry serious safety risks according to medical experts. The issue affects Medicaid beneficiaries who may turn to compounded versions due to cost or access barriers with brand-name GLP-1s. This raises questions for state Medicaid programs about coverage policies, prior authorization criteria, and quality oversight for diabetes and weight management drugs.
- Industry
Danish Study Finds GLP-1 Drugs Reduce Long-Term Sick Leave by 17%
A study based on Danish data found that patients taking GLP-1 drugs experienced 17% fewer long-term work absences compared to those not on the medications. The research examined workplace absenteeism patterns among GLP-1 users. The findings suggest potential broader economic benefits beyond direct health outcomes. For Medicaid programs covering GLP-1s for weight management or diabetes, this data may inform cost-benefit analyses around coverage decisions, though workforce participation effects in Medicaid populations may differ from the Danish workforce studied.
- Industry
Study Finds GLP-1 Drugs Reduce Long-Term Sick Leave by 17 Percent
A study using Danish data found that patients taking GLP-1 medications had 17 percent fewer long-term sick leave absences compared to those not on the drugs. The research suggests potential workforce participation and productivity benefits beyond clinical outcomes for obesity and diabetes treatment. The findings may inform Medicaid coverage decisions and utilization management policies for GLP-1s, which have been subject to state budget scrutiny due to high costs. The study did not specify implementation timelines but reflects ongoing evaluation of these drugs' broader economic impacts.
- Federal Policy
Trump Announces 100% Tariff on Imported Generics Effective August 2028
President Trump announced Tuesday via social media that imported generic drugs will face a 100 percent tariff beginning in August 2028 unless manufacturers relocate production to the United States. The tariff is described as a penalty designed to reshore generic pharmaceutical manufacturing. Generic drugs constitute the majority of Medicaid pharmacy spending, and most generics dispensed in the U.S. are manufactured overseas or contain active pharmaceutical ingredients from foreign suppliers. The two-year implementation timeline provides MCOs and state programs time to assess potential pharmacy cost impacts and supply chain disruptions.
- Federal Policy
Senate Democrat Proposes Medicare Enrollment for All Children Under Age 26
Sen. Andy Kim (D-N.J.) introduced legislation to automatically enroll all American children in Medicare from birth through age 25, calling the proposal MediKids. The bill would create universal federal coverage for children regardless of family income. No timeline for committee consideration or floor action has been announced. The proposal would fundamentally restructure pediatric coverage currently delivered through Medicaid, CHIP, and commercial insurance, though passage prospects remain uncertain given divided government.
- Federal Policy
Medicare Part D Now Covers GLP-1s for Weight Loss Under New CMS Policy
Insurance coverage for GLP-1 medications used for weight loss has changed for approximately 56 million Americans. The policy shift affects Medicare Part D beneficiaries and potentially other federal health programs. The coverage expansion comes as GLP-1 drugs like Ozempic and Wegovy gain widespread use for obesity treatment. Medicare previously covered these medications only for diabetes, not weight management alone, making this a significant benefit expansion with major cost implications for plans and enrollees.
- Federal Policy
Planned Parenthood Medicaid Funding Prohibition Excluded from GOP Reconciliation Framework
Republicans' reconciliation 3.0 framework omits language that would prohibit Medicaid funding from flowing to abortion providers like Planned Parenthood, prompting intensified activism from anti-abortion groups. The exclusion marks a potential shift in Republican legislative strategy on reproductive health provider funding within Medicaid. No timeline for final reconciliation language has been announced. The omission affects managed care organizations that currently contract with or reimburse Planned Parenthood affiliates for covered Medicaid services in states that have not already enacted provider exclusions.
- Federal Policy
Senate Questions CDC and HHS Nominees on Vaccine Policy Alignment
Two Trump administration health nominees—Erica Schwartz for CDC Director and Sean Kaufman for an HHS position—faced Senate scrutiny on July 15, 2026, over their willingness to challenge administration positions on vaccines. Both Democrats and some Republicans expressed concern about the nominees' reluctance to break with administration policy. The hearing centered on whether the nominees would maintain agency independence on vaccine policy and public health guidance. Confirmation votes have not been scheduled.
- Federal Policy
Acting AG Pledges Federal Action to Restrict Mail Order Mifepristone
Acting Attorney General Todd Blanche told Republican senators he will prioritize stopping abortion medication from being mailed to patients if confirmed. Blanche specifically opposes the Biden-era policy that permitted mail distribution of mifepristone but did not detail enforcement mechanisms or timeline. The commitment signals potential federal action against telehealth abortion services and mail-order pharmacy dispensing of medication abortion. Any DOJ enforcement action could affect Medicaid managed care plans that cover telehealth reproductive services and pharmacy benefits including mifepristone.
- Federal Policy
HHS Secretary Kennedy Blocks Preventive Services Task Force Meetings, Fires Leadership
HHS Secretary Robert F. Kennedy Jr. has prevented the U.S. Preventive Services Task Force from meeting, declined to replace members whose terms have expired, and fired the panel's leaders in May 2026. The task force determines which preventive medical services insurers must cover without cost-sharing under the Affordable Care Act. The disruption affects coverage recommendations for screenings, counseling, and preventive medications that Medicaid managed care plans must cover as essential health benefits. The timeline for new coverage recommendations and the panel's future composition remain uncertain.
- Federal Policy
FDA Approves Gene Therapy for Children with Sickle Cell Disease
The FDA has approved a new gene therapy treatment for children aged 2 and older with sickle cell disease. The approval expands treatment options for pediatric patients with this serious inherited blood disorder, which disproportionately affects Medicaid beneficiaries. Sickle cell disease affects approximately 100,000 Americans, with the majority covered by Medicaid. Managed care organizations will need to evaluate coverage policies, establish prior authorization criteria, and assess the financial impact of this high-cost specialty therapy on capitation rates and medical loss ratios.
- Managed Care
GLP-1 Weight Loss Use Jumps to 11% of Americans in Two Years
A Gallup survey released Tuesday shows 11 percent of Americans now take GLP-1 medications for weight loss, up from 3 percent in 2024. An additional 15 percent report considering use. The sharp uptick in utilization represents significant pharmacy cost pressure for Medicaid managed care plans, which face coverage mandates in some states and growing member demand. Plans must manage prior authorization protocols, medical necessity criteria, and budget forecasts as obesity prevalence grows among Medicaid populations.
- Federal Policy
DEA Proposes Schedule I Classification for Synthetic Kratom Compound 7-OH
The Drug Enforcement Administration announced plans to temporarily classify 7-hydroxymitragynine (7-OH) and three related synthetic kratom compounds as Schedule I controlled substances, placing them in the same regulatory category as heroin and LSD. The classification applies to synthetic versions of the psychoactive compound found in kratom products. If finalized, the scheduling action would prohibit manufacture, distribution, and possession of these substances, with enforcement implications for entities handling these compounds. The timing of implementation and comment period was not specified in the available content.
- Industry
PBM Trade Group Escalates Advocacy Against Drugmakers Following Congressional Overhaul
The leading pharmacy benefit manager lobbying organization is intensifying its advocacy campaign against pharmaceutical manufacturers after Congress enacted comprehensive PBM reform legislation earlier this year. The pharmaceutical industry has long blamed PBMs for high drug costs, culminating in legislative action this past winter. The lobbying escalation suggests ongoing tension between PBMs and drugmakers over responsibility for drug pricing and the implementation of new federal oversight provisions that affect both sectors.
- Federal Policy
Sanders Releases HHS Emails Showing Kennedy Pressured CDC on Vaccine Messaging
Senator Bernie Sanders released internal HHS emails indicating that HHS Secretary Robert F. Kennedy Jr. pressured the CDC to alter vaccine messaging and directed the CDC's vaccine advisory panel to restrict vaccine access. The emails document direct intervention in CDC communications and advisory processes. The release comes amid ongoing scrutiny of the administration's vaccine policy direction and its potential impact on public health programs.
- Legal · NY
Federal Judge Blocks DOJ Subpoenas for Transgender Patient Records at NYC Hospitals
A federal district court issued a temporary restraining order blocking the Justice Department from obtaining medical records of transgender patients treated at New York City hospitals. The ruling halts an ongoing DOJ investigation into gender-affirming care provided at these facilities. The order provides immediate protection for patient records while the case proceeds. The decision affects hospitals treating Medicaid beneficiaries receiving gender-affirming services and raises questions about federal enforcement priorities and patient privacy protections.
- Federal Policy
Senate Democrats Challenge Trump Administration's Moms.gov Site Over Crisis Pregnancy Center Listings
Eleven Democratic senators raised concerns about the Trump administration's Moms.gov website, launched on Mother's Day, which features resources from 2,750 pregnancy centers. The lawmakers argue the site directs families to crisis pregnancy centers rather than licensed medical providers. The site provides information for new and expecting mothers, but critics including Planned Parenthood contend these centers do not provide comprehensive medical care. The senators' letter signals potential congressional oversight of federal maternal health resource guidance.
- Industry
Meta-Analysis Compares Weight Loss Efficacy Across Tirzepatide, Semaglutide, and Liraglutide
A new meta-analysis compared weight loss outcomes for three GLP-1 receptor agonists: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated clinical efficacy data across the three drug classes to determine comparative effectiveness for weight management. The findings provide evidence that could inform prior authorization criteria, formulary placement, and medical policy for obesity treatment in Medicaid managed care plans. Many state Medicaid programs have restricted or excluded coverage of anti-obesity medications due to cost, making comparative effectiveness data particularly relevant for coverage and utilization management decisions.
- Federal Policy
Senate Democrats Investigate HHS Changes to Federal Vaccine Advisory Panel
Senate Democrats Ron Wyden and Maggie Hassan have launched an investigation into Health Secretary Robert F. Kennedy Jr.'s restructuring of the Advisory Committee on Immunization Practices (ACIP), the federal panel that issues vaccine recommendations. The senators are demanding communications and records showing who determined the legal and public health consequences of remaking the advisory committee. ACIP recommendations typically inform Medicaid and CHIP coverage decisions for vaccines under the Vaccines for Children program and mandatory coverage requirements for pediatric vaccines. The investigation seeks transparency around the decision-making process that led to changes in the federal vaccine policy infrastructure.
- Federal Policy
FDA Approves Third Over-the-Counter Naloxone Nasal Spray
The FDA approved Rextovy, a 4mg naloxone nasal spray, for over-the-counter sale in pharmacies, convenience stores, and online for emergency treatment of opioid overdose. This is the third OTC naloxone product approved by FDA. The approval expands consumer access to overdose reversal medication without a prescription. For Medicaid managed care organizations, this may affect pharmacy benefit management, member education strategies, and harm reduction program design, particularly for plans serving populations with substance use disorders.
- Federal Policy
Senate Democrats Release Prescription Drug Pricing Policy Blueprint
Senate Democrats released a policy blueprint proposing measures to lower prescription drug costs ahead of the midterm elections. The proposals aim to address voter concerns about drug affordability and provide a counter-message to White House voluntary pricing initiatives. The blueprint reflects ongoing bipartisan interest in drug pricing reform but does not specify legislative text, implementation timelines, or comment periods. For Medicaid managed care organizations, potential reforms could affect pharmacy benefit management, capitation rate calculations, and prescription drug rebate programs.
- Federal Policy
HHS Secretary Kennedy Demands Explanation for Retracted Vaccine-SIDS Study
HHS Secretary Robert F. Kennedy Jr. sent a June 11 letter to the editor-in-chief of Toxicology Reports demanding justification for the removal of a 2021 study linking vaccines to sudden infant death syndrome. Kennedy has cited this research in support of proposed changes to childhood immunization schedules. The retraction raises questions about the scientific basis for potential federal policy shifts affecting Medicaid-covered pediatric vaccine programs. No timeline has been announced for HHS policy changes to childhood vaccination requirements.
- Legal · AK
Planned Parenthood Sues Alaska Over Medication Abortion Telehealth Ban
Planned Parenthood Great Northwest filed a lawsuit Thursday in Alaska state court challenging the state's requirement that medication abortion be provided only in person, arguing it violates Alaska's constitutional right to abortion. The lawsuit seeks a preliminary injunction against the telehealth ban. Alaska is among states restricting medication abortion access through telehealth despite broader telemedicine expansion. The case affects how Medicaid managed care plans handle abortion coverage and telehealth protocols in Alaska, particularly for reproductive health services where telehealth has become standard in other states.
- Federal Policy
Six States Report Higher-Than-Expected ACA Marketplace Attrition After Enhanced Subsidies Expired
State-level enrollment data through April 2026 from Arkansas, Colorado, Maryland, Massachusetts, New Mexico, and New York show significant coverage losses as enrollees canceled plans or stopped paying premiums following the expiration of enhanced ACA subsidies. Georgetown University analysis indicates attrition rates exceed initial federal projections. Congress did not renew the enhanced subsidies that had been in place, resulting in higher premium costs for marketplace enrollees. The coverage losses could affect Medicaid managed care organizations in states with integrated or coordinated care models between marketplace and Medicaid coverage.
- Federal Policy
ACOG Issues Maternal Vaccine Schedule Diverging from CDC Guidance
The American College of Obstetricians & Gynecologists released a recommended maternal vaccine schedule that differs from CDC guidance for the first time. ACOG recommends four vaccines during pregnancy: influenza, COVID-19, Tdap, and RSV. The new schedule affects prenatal care protocols and provider counseling for pregnant Medicaid beneficiaries. This divergence creates potential confusion for managed care organizations that must decide whether to align coverage policies and quality metrics with CDC or ACOG recommendations for their maternal health programs.
- Industry
Trump Administration Adds 160 Drugs to TrumpRx Direct-to-Consumer Platform
President Trump announced Friday that TrumpRx.gov will add 160 prescription medications to its direct-to-consumer platform, bringing the total to over 800 drugs available at discounted prices. This marks the second expansion of the initiative in two months. The platform sells drugs directly to consumers, bypassing traditional pharmacy channels. The announcement did not specify which drugs were added or provide details about pricing structures or manufacturer participation.
- Federal Policy
CDC Reports Over 2,000 Measles Cases in 2026, 93% Outbreak-Related
The CDC confirmed 2,030 measles cases in the U.S. as of June 4, 2026, with 1,890 cases (93%) linked to outbreaks. This total is rapidly approaching the full-year 2025 count. Measles is a highly contagious vaccine-preventable disease that poses particular risks to immunocompromised populations and young children. For Medicaid managed care plans, rising case counts may trigger increased EPSDT screening requirements, higher utilization of pediatric acute care and emergency services, and potential quality measure impacts related to childhood immunization rates.
- Federal Policy
FDA Launches Safety Review of Abortion Drug Mifepristone
The Food and Drug Administration has initiated a safety review of mifepristone, the abortion medication, according to an administration official. The retrospective analysis could lead to restrictions on the drug's use and distribution channels. Anti-abortion groups view this as a significant development that may result in tighter federal controls over medication abortion access. The timing and scope of the review have not been disclosed.
- Federal Policy
Senator Cassidy Blames HHS Secretary Kennedy for Rise in Vaccine-Preventable Diseases
Sen. Bill Cassidy (R-La.) publicly blamed HHS Secretary Robert F. Kennedy Jr. for a resurgence in vaccine-preventable diseases, citing a New York Times report that hospitals are seeing illnesses previously controlled by childhood immunizations. The statement comes as doctors report increased cases of diseases they rarely encountered in recent years. The criticism targets Kennedy's well-documented skepticism of vaccines and his influence over federal health policy. No immediate policy change or enforcement action has been announced.
- Legal · HI
HHS OIG Defunds Hawaii Medicaid Fraud Control Unit After Four Years Without Indictments
The HHS Office of Inspector General will not recertify Hawaii's Medicaid Fraud Control Unit, cutting off $3 million in federal funding after the unit failed to produce any indictments or convictions over four years. Inspector General March Bell notified Hawaii Attorney General Anne Lopez of the decision in a letter. The decertification means Hawaii loses federal matching funds for its MFCU operations. This is the first known instance of OIG defunding a state MFCU for performance failure.
- Federal Policy
CMS Administrator Oz to Lead White House Press Briefing
Dr. Mehmet Oz, Administrator of the Centers for Medicare and Medicaid Services, will conduct the White House press briefing on Tuesday. He is filling in for press secretary Karoline Leavitt during her maternity leave, joining other Cabinet officials who have taken on briefing duties. The briefing may provide insight into CMS priorities and policy direction under the current administration. Managed care organizations should monitor for any announcements regarding Medicaid policy, regulatory changes, or administrative guidance that could affect program operations.
- Federal Policy
Trump Executive Order Endorses HHS Reduction in Required Childhood Vaccinations
President Trump signed an executive order Friday endorsing HHS's decision to reduce required childhood vaccinations. The order cites religious liberty and parental rights as justification for adjusted immunization requirements. The policy change affects federally recommended vaccine schedules that states and health plans use for EPSDT and well-child care compliance. Medicaid managed care organizations must monitor whether state Medicaid agencies adjust their EPSDT screening requirements in response, which could impact quality metrics, HEDIS measures, and contractual performance standards tied to childhood immunization rates.
- Managed Care
UnitedHealthcare Eliminates Two-Thirds of Pediatric Prior Authorization Requirements by Year-End
UnitedHealthcare announced it will remove prior authorization requirements for the majority of pediatric services for members under age 18 by the end of the year, eliminating two-thirds of current authorization requirements. The change affects commercial and Medicare Advantage plans with pediatric enrollment. The policy takes effect by December 31, 2024. This reflects growing pressure on health plans to reduce administrative burden and aligns with broader industry and regulatory momentum toward prior authorization reform, potentially setting a benchmark other Medicaid MCOs may need to match.